Your Health, We Care
The indications of Afatinib continue to expand, including the treatment of HER2 positive patients with advanced breast cancer, and patients with advanced lung squamous cell carcinoma after first-line chemotherapy.
The FDA has also approved Afatinib for the treatment of metastatic NSCLC patients carrying uncommon EGFR mutations (L861Q, G719X, and/or S768I).
